Kazia Therapeutics (KZIA) Research & Development (2009 - 2016)

Kazia Therapeutics (KZIA) posted Research & Development of -$3.7 million for Q4 2016, down 3192.16% on a QoQ basis from -$111215.5 in Q4 2011.

Kazia Therapeutics (KZIA) Research & Development (2009 - 2016) Analysis & Trends

Kazia Therapeutics' Research & Development history runs 3 years deep, the most recent figure standing at -$3.7 million for Q4 2016.

Quarterly Research & Development changed N/A year-over-year to -$3.7 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$15.7 million (changed N/A YoY) and the FY2025 annual result came in at $4.7 million, down 59.04% from the prior year.
Research & Development was -$3.7 million for Q4 2016 at Kazia Therapeutics, down from -$111215.5 in the prior quarter.
Across five years, Research & Development topped out at -$3.7 million in Q4 2016 and bottomed at -$3.7 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	R&D (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-17.94 Mn
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	1.46 Mn
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	541.22 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	961.60 Mn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	1.54 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	15.66 Mn
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-443.00 Mn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	343.97 Mn
10	Kazia Therapeutics	19.25 Bn	19.25 Bn	-	-

Download Data